2026 Goals
With ANVISA certified and FDA strategy defined, 2026 focuses on scaling revenue through segment specialization while expanding into the UK market and completing the CE Mark MDR transition.
Revenue
| Metric | Target | Baseline (2025) |
|---|---|---|
| Revenue | €1.3M | €604,495 |
| Invoiced | €1.0M | €847,778 |
| Growth | 2.15x | — |
Market Expansion
Target: 1 new market
Priority market: United Kingdom
Regulatory Certification
| Certification | Market | Target |
|---|---|---|
| CE Mark MDR | European Union | Certified (MDD→MDR transition) |
| FDA 510(k) | United States | Pre-submission |
Customer Success
| Metric | Target | Frequency |
|---|---|---|
| CSAT | >75% | Quarterly |
| Top-half retention | >90% | Annual |
| Bottom-half retention | >85% | Annual |
Focus: Establish systematic CSAT measurement that was missing in 2024 and 2025.